MARA Holdings
MARA
MicroStrategy
MSTR
Coinbase
COIN
Tesla
TSLA
Amazon
AMZN
US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 4.3300
- +0.0400+0.93%
Close Jan 17 16:00 ET
- 4.3300
- 0.00000.00%
Post 20:01 ET
90.07MMarket Cap-0.73P/E (TTM)
4.3800High4.2200Low120.37KVolume4.3300Open4.2900Pre Close520.83KTurnover1.04%Turnover RatioLossP/E (Static)20.80MShares29.700052wk High0.63P/B50.09MFloat Cap4.010052wk Low--Dividend TTM11.57MShs Float624.8000Historical High--Div YieldTTM3.73%Amplitude4.0100Historical Low4.3270Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Adverum Biotechnologies Stock Forum
📊⚡️📊
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
$EyePoint Pharmaceuticals (EYPT.US)$
$Adverum Biotechnologies (ADVM.US)$
$Regenxbio (RGNX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Kodiak Sciences (KOD.US)$
No comment yet